Role of different proteolytic systems in the degradation of muscle proteins during denervation atrophy.
In order to clarify the cellular mechanisms of denervation atrophy of skeletal muscle, we have studied protein turnover in denervated and control rat soleus muscles in vitro under different conditions. By 24 h after cutting the sciatic nerve, overall protein breakdown was greater in the denervated soleus than in the contralateral control muscle, and by 3 days, net proteolysis had increased about 3-fold. Since protein synthesis increased slightly following denervation, the rise in proteolysis must be responsible for the muscle atrophy and the differential loss of contractile proteins. Like overall proteolysis, the breakdown of actin (as shown by 3-methyl-histidine production by the muscles) increased each day after denervation and by 3 days was 2.5 times faster than in controls. Treatments that block the lysosomal and Ca2(+)-dependent proteolytic systems did not reduce the increase in overall protein degradation and actin breakdown in the denervated muscles (maintained in complete medium at resting length). However, the content of the lysosomal protease, cathepsin B, increased about 2-fold by 3 days after denervation. Furthermore, conditions that activate intralysosomal proteolysis (incubation without insulin or amino acids) stimulated proteolysis 2-3-fold more in the denervated muscles than in controls. Also, incubation conditions that activate the Ca2(+)-dependent pathway (incubation with Ca2+ ionophores or allowing muscles to shorten) were 2-3 times more effective in enhancing overall proteolysis in the denervated muscle. None of these treatments affected 3-methylhistidine production. Thus, multiple proteolytic systems increase in parallel in the denervated muscle, but a nonlysosomal process (independent of Ca2+) appears mainly responsible for the rapid loss of cell proteins, especially of myofibrillar components.
Department of Cellular and Molecular Physiology, Harvard Medical School, Boston, Massachusetts 02115.
K
K
Furuno
M N
MN
Goodman
A L
AL
Goldberg
D000199:Actins / Q000378:metabolism; D000818:Animals; D001284:Atrophy; D002401:Cathepsin B / Q000378:metabolism*; D007328:Insulin / Q000494:pharmacology; D008247:Lysosomes / Q000201:enzymology; D008297:Male; D008762:Methylhistidines / Q000032:analysis; D009121:Muscle Denervation; D009124:Muscle Proteins / Q000378:metabolism*; D009132:Muscles / Q000294:innervation / Q000378:metabolism* / Q000473:pathology; D009210:Myofibrils / Q000378:metabolism; D010447:Peptide Hydrolases / Q000378:metabolism*; D011480:Protease Inhibitors / Q000494:pharmacology; D051381:Rats; D011919:Rats, Inbred Strains; D012016:Reference Values; D012519:Sarcoplasmic Reticulum / Q000378:metabolism
D000199:Actins; D007328:Insulin; D008762:Methylhistidines; D009124:Muscle Proteins; D011480:Protease Inhibitors; D010447:Peptide Hydrolases; D002401:Cathepsin B; C028118:3-methylhistidine